Home
February 2010 March 2010 April 2010
Su Mo Tu We Th Fr Sa
Week 9 1 2 3 4 5 6
Week 10 7 8 9 10 11 12 13
Week 11 14 15 16 17 18 19 20
Week 12 21 22 23 24 25 26 27
Week 13 28 29 30 31
Reach urologists

Overactive Bladder
UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.
Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Search    Display results per page
Results 16 - 30 of 758
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: Results from the SUmiT trial - Abstract
Friday, 05 March 2010
Beaumont Hospital, Royal Oak, Michigan.
read more

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial - Abstract
Thursday, 04 March 2010
Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, Ontario, Canada.
read more

Beyond the Abstract - Fesoterodine for the treatment of urinary incontinence and overactive bladder, by Pamela Ellsworth, MD
Wednesday, 03 March 2010
BERKELEY, CA (UroToday.com) - The first placebo-controlled superiority trial between two antimuscarinic agents was recently performed comparing fesoterodine 8mg to tolterodine ER 4mg and placebo.
Login to read more...

Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication? - Abstract
Monday, 01 March 2010
Urodynamic Urology Unit, Department of Urology, Medical School, University of Patras, Patras, Greece.
read more

Functional results following vescica ileale Padovana (VIP) neobladder: Midterm follow-up analysis with validated questionnaires - Abstract
Monday, 01 March 2010
Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Italy.
read more

Ultrasound measurement of bladder wall thickness is associated with the overactive bladder syndrome - Abstract
Monday, 01 March 2010
Imperial College Healthcare NHS Trust, London, UK.
read more

Female sexual abuse evaluation in the urological practice: Results of a Dutch survey - Abstract
Monday, 01 March 2010
Leiden University Medical Center-Urology, Leiden, the Netherlands.
read more

Efficacy of fesoterodine over 24 hours in subjects with overactive bladder - Abstract
Friday, 26 February 2010
Tufts University School of Medicine, Boston, MA, USA.
read more

Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes - Abstract
Friday, 26 February 2010
Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Rd, Bristol, BS8 2PS, UK.
read more

Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children - Abstract
Thursday, 25 February 2010
Pediatric Surgery-Second University of Naples, Pediatrics, Naples, Italy.
read more

Defining efficacy in the treatment of overactive bladder syndrome - Abstract
Wednesday, 24 February 2010
Department of Urology, New York University School of Medicine New York, NY.
read more

Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes - Abstract
Tuesday, 23 February 2010
Department of Urology, National Taiwan University Hospital and College of Medicine, and Department of Internal Medicine, Division of Endocrinology and Metabolism, National Taiwan University Hospital, Taipei 10002, Taiwan.
read more

Lower urinary tract symptoms in women with irritable bowel syndrome - Abstract
Friday, 19 February 2010
Department of Psychiatrics, Heping Branch, Taipei City Hospital, Taipei, Taiwan.
read more

WUF 2010 - Slide Presentation - Practical urodynamics in female urology
Thursday, 18 February 2010
VAIL, CO, USA - Presented by J. Quentin Clemens, MD, FACS, MSCI at the 34th Winter Urologic Forum - January 29-February 2, 2010, Vail, Colorado, USA
Login to read more...

WUF 2010 - Slide Presentation - Pharmacotherapy for OAB and stress incontinence
Wednesday, 17 February 2010
VAIL, CO, USA - Presented by J. Quentin Clemens, MD, FACS, MSCI at the 34th Winter Urologic Forum - January 29-February 2, 2010, Vail, Colorado, USA
Login to read more...




Promoting World Continence




Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.





Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy






Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years

- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy

- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment

- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder

- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity

- by Marcus Drake, MD



Two Types of Urgency

- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity

- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity

- by Philip M. Hanno, MD, MPH



Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review

- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder

- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing

- by Ulrich Schwantes, PhD, et al.






The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?



On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise




A Review of Adherence to Drug Therapy in Patients with Overactive Bladder



Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience




Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study

- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release

- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery

- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder

- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder

- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder

- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years

- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome

- by Ling-Hong Tseng, MD, et al.









The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder

- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?

- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?

- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder

- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting

- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium

- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series


- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)


Drug Treatment - Committee Meeting Highlights


- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights


- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality


- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder

- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008

- Session Abstracts, Overactive Bladder
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 16 - 30 of 758
back

UroToday, 1802 Fifth Street, Berkeley CA 94710
510.540.0930 (fax), info@urotoday.com
ISSN 1939-4810
UroToday International Journal Correspondence
About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use


Privacy Policy | © 2010 UroToday ® All Rights Reserved

Member's Section

Login

Sign Up

Quick Search


Advanced Search

Meet the Expert


All Experts



Featured Conference

Media and Publisher

Advertising Rates

Working with Industry

Case Studies
Sponsorship Opportunities

Overactive Bladder
Sponsored By